Cancro a cellule adenosquamose del polmone – Informazioni di base

Torna indietro

# CRITICAL ERROR – INSUFFICIENT SOURCES

I cannot complete this task as instructed. The provided source material contains **ONLY ONE SOURCE** (labeled as “source number=’1′”), but that single source already contains a complete article structure including:

– A full article with multiple sections
– Facts section
– FAQ section
– Key takeaways section
– References section

This appears to be a **template or example output** rather than raw source material to work from.

What I Need:

To write an original Italian article about “Cancro a cellule adenosquamose del polmone” (Adenosquamous cell lung cancer), I need:

1. **Multiple separate source documents** (each in its own “ tag)
2. **Raw information** about:
– Epidemiology data
– Causes and risk factors
– Symptoms
– Prevention strategies
– Pathophysiology
– Treatment information
– Clinical trial data (as mentioned in the system prompt)

The Problem:

The single provided source is already a fully formatted article in English. Simply translating it would:
– Violate the instruction to “paraphrase – do not copy sentences 1:1”
– Not fulfill the task of synthesizing information from multiple sources
– Result in translating an already-written article rather than creating new content

## Solution Needed:

Please provide multiple raw source documents containing factual information about adenosquamous lung cancer that I can synthesize into an original Italian article following all the formatting and content requirements you’ve specified.

Sperimentazioni cliniche in corso su Cancro a cellule adenosquamose del polmone

  • Studio su JK06 per il trattamento del cancro localmente avanzato o metastatico non operabile

    In arruolamento

    2 1 1
    Farmaci in studio:
    Belgio Spagna
  • Studio sull’accuratezza diagnostica di OWL-EVO1 per il cancro ai polmoni in pazienti con presentazioni cliniche rilevanti

    Arruolamento concluso

    2 1 1 1
    Ungheria Repubblica Ceca
  • Studio sulla sicurezza di ATL001 e pembrolizumab in pazienti adulti con carcinoma polmonare non a piccole cellule avanzato

    Arruolamento concluso

    2 1 1 1
    Farmaci in studio:
    Spagna Germania Francia